AlphAIAlphAI — Financial news for AI agents
SEC EDGARSEP 151 min read$MNKD

Binder Steven B. sold $128K of MNKD

Binder Steven B. sold 33,558 shares of MANNKIND CORP (MNKD) at $3.81 ($0.13M total) on 2026-09-10 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Binder Steven B.
Published Sep 15, 2026, 12:00 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 15, 2026, 12:38 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefInsider activity
Primary signal
$MNKD
Neutral
medium confidence
Mentioned
$MNKD
Relevance
3/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$MNKDNeutralLow
01

Why it matters

The director's sale is modest; investors may monitor for further insider activity.

02

Market read

Minor insider sale with limited trading relevance.

03

What to watch

Potential upcoming clinical trial results or financing events not disclosed.

Relevance 3/10Novelty 4/10Timing: filing date 2026-09-14, after market close

Background

SEC Form 4 filing discloses insider transactions; this is the first public report of the sale.

Company-level read

Ticker impact

$MNKDNeutralMedium confidence
Context

Director Binder Steven B. sold 33,558 shares of MannKind Corp for $127,856 via a 10b5-1 plan.

Expected impact

Limited short-term pressure; unlikely to move price materially.

Evidence & confidence

Sale size (~$128K) is small compared to total holdings (752,309 shares) and market cap, so impact is minimal.

Market effects

Sector

No broader sector impact; MannKind operates in biotech niche.

Regional

None

Global

None

Counterpoint

What could challenge this read

The sale could be routine liquidity need rather than a negative signal.

Key entities

  • Company
    MannKind Corp

    Biopharmaceutical company developing inhalable insulin.

  • Individual
    Binder Steven B.

    Director of MannKind Corp.

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

MNKD insider trading history →

Related articles

AUG 24
$UTHRMedAI 9/10

FDA accepts United Therapeutics' ralinepag NDA for PAH

The FDA accepted United Therapeutics' NDA for ralinepag, a PAH treatment, with a PDUFA target date of June 24, 2027. The application is based on Phase III trial results showing a 55% reduction in clinical worsening events. If approved, ralinepag would be the first once-daily oral prostacyclin IP receptor agonist for PAH. The company also plans to develop a dry powder inhalation formulation with MannKind.

allsci.com2 min
AUG 10
$MNKDMed

CT companies take different paths to finance growth

Three Connecticut firms outlined different financing paths. New Silver said it acquired Mayflower Venture Partners to expand lending in New England, with deal terms undisclosed. American Battery Materials filed to raise about $16.3M for Utah lithium and magnesium exploration, targeting production in 2029. MannKind raised $50M after FDA approval of Furoscix ReadyFlow, funding a $45M milestone payment and aiming for U.S. sales by end-August.

hartfordbusiness.com6 min
AUG 5
$MNKDMedAI 8/10

MannKind Reports Second Quarter 2026 Financial Results and Provides Business Update

MANNKIND CORP (MNKD) filed an SEC Form 8-K — Results of Operations and Financial Condition. MannKind Reports Second Quarter 2026 Financial Results and Provides Business Update • Achieved three major catalysts to drive future growth: o Launched the pediatric indication of Afrezza ® following FDA approval o FUROSCIX ReadyFlow™ autoinjector approved for treatment of edema

SEC EDGAR 8-K4 min